Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

EUA Expanded for Lilly COVID Combo Therapy

Friday, December 3, 2021 07:16 PM EDT
By Alex Brown
estesevimab bamlanivimab Products
(Provided Photo/Eli Lilly and Co.)

The U.S. Food and Drug Administration has expanded the Emergency Use Authorization for a combination therapy developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) to treat patients with COVID-19. Lilly says bamlanivimab and etesevimab can now be used to treat certain high-risk pediatric patients from birth to 12 years old.

The company says the expansion is based on a Phase 2/3 clinical trial of the combination therapy being administered for the treatment of mild-to-moderate COVID-19 among pediatric and infant patients, as well as those who are at high risk for severe disease progression.

“Our mission since the start of the pandemic has been to offer crucial support by developing therapeutic options that could prevent hospitalization and death for as many people as possible,” said Dr. Daniel Skovronsky, chief scientific and medical officer at Lilly and president of Lilly Research Laboratories. “With the FDA’s decision to allow use of bamlanivimab with etesevimab in children and infants, Lilly can now offer treatment and prevention options to high-risk individuals of any age.”

The combination therapy initially received an EUA in February for use in patients 12 years and older.

Lilly says, to date, more than 700,000 patients have been treated with either the combination therapy or bamlanivimab alone.

Story Continues Below

Most Popular Stories

  • An Angola company is making tech last longer. Its mission has led to big growth.

  • Shoe Carnival names new CFO

  • Evansville’s West Side Nut Club Fall Festival tops USA Today’s list of best fall festivals

  • Purdue to develop SARS-CoV-2 animal field test

  • Lilly to install $10M worth of solar panels at two Indy campuses

  • Indiana utilities outline outages, responses to major storms

Perspectives

Biodefense Commission heads to IMS for a public meeting on the perpetual race against biological threats

Biodefense Commission heads to IMS for a public meeting on the perpetual race against biological threats

The Indianapolis Motor Speedway has hosted countless legendary events for well over 100 years. Along with Lucas Oil Stadium, Gainbridge Fieldhouse and the Indiana Convention Center, Indianapolis hosts countless large scale, mass-gathering events. It is part of what makes this city so dynamic and special. ...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service